|
|
Found results for
 patents
1.
|
Method for producing a nanostructured complex (CFI-1), a protein-associated nanostructured complex (MRB-CFI-1) and use
| Application Number |
17236848 |
| Grant Number |
11572284 |
| Status |
In Force |
| Filing Date |
2021-04-21 |
| First Publication Date |
2021-08-05 |
| Grant Date |
2023-02-07 |
| Owner |
UNIVERSIDADE ESTADUAL DE CAMPINAS—UNICAMP (USA)
|
| Inventor |
- Favaro, Wagner José
- Caballero, Nelson Eduardo Duran
|
Abstract
Disclosed is a method of obtaining a protein-associated nanostructured complex (MRB-CFI-1) by chemical synthesis and antitumor use. The main use is in treating cancer, both in animals and humans. The complex has singular antitumor activity, and can potentially be used as a substitute and/or act as an adjuvant for other commercial antineoplastic drugs.
IPC Classes ?
- C01C 1/02 - Preparation or separation of ammonia
- A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00 - Antineoplastic agents
- A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- C01B 25/02 - Preparation of phosphorus
- C01F 5/32 - Preparation of anhydrous magnesium chloride by chlorinating magnesium compounds
- A61K 38/00 - Medicinal preparations containing peptides
- B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- B82Y 40/00 - Manufacture or treatment of nanostructures
|
2.
|
Method for producing a nanostructured complex (CFI-1), a protein-associated nanostructured complex (MRB-CFI-1) and use
| Application Number |
17236839 |
| Grant Number |
11623869 |
| Status |
In Force |
| Filing Date |
2021-04-21 |
| First Publication Date |
2021-08-05 |
| Grant Date |
2023-04-11 |
| Owner |
UNIVERSIDADE ESTADUAL DE CAMPINAS—UNICAMP (USA)
|
| Inventor |
- Favaro, Wagner José
- Caballero, Nelson Eduardo Duran
|
Abstract
Disclosed is a method of obtaining an inorganic nanostructured complex (CFI-1) by chemical synthesis and antitumor use. The main use is in treating cancer, both in animals and humans. The complex has singular antitumor activity, and can potentially be used as a substitute and/or act as an adjuvant for other commercial antineoplastic drugs.
IPC Classes ?
- C01C 1/02 - Preparation or separation of ammonia
- A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00 - Antineoplastic agents
- A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- C01B 25/02 - Preparation of phosphorus
- C01F 5/32 - Preparation of anhydrous magnesium chloride by chlorinating magnesium compounds
- A61K 38/00 - Medicinal preparations containing peptides
- B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- B82Y 40/00 - Manufacture or treatment of nanostructures
|
3.
|
Method for producing a nanostructured complex (CFI-1), a protein-associated nanostructured complex (MRB-CFI-1) and use
| Application Number |
17236861 |
| Grant Number |
11639294 |
| Status |
In Force |
| Filing Date |
2021-04-21 |
| First Publication Date |
2021-08-05 |
| Grant Date |
2023-05-02 |
| Owner |
UNIVERSIDADE ESTADUAL DE CAMPINAS—UNICAMP (USA)
|
| Inventor |
- Favaro, Wagner José
- Caballero, Nelson Eduardo Duran
|
Abstract
2O associated or not to hydrolytic enzymes, which are known to have immunomodulatory activities.
IPC Classes ?
- C01C 1/02 - Preparation or separation of ammonia
- A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00 - Antineoplastic agents
- A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- C01B 25/02 - Preparation of phosphorus
- C01F 5/32 - Preparation of anhydrous magnesium chloride by chlorinating magnesium compounds
- A61K 38/00 - Medicinal preparations containing peptides
- B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- B82Y 40/00 - Manufacture or treatment of nanostructures
|
4.
|
Method for producing a nanostructured complex (CFI-1), a protein-associated nanostructured complex (MRB-CFI-1) and use
| Application Number |
16617493 |
| Grant Number |
11136242 |
| Status |
In Force |
| Filing Date |
2018-06-14 |
| First Publication Date |
2020-05-21 |
| Grant Date |
2021-10-05 |
| Owner |
UNIVERSIDADE ESTADUAL DE CAMPINAS—UNICAMP (USA)
|
| Inventor |
- Favaro, Wagner José
- Caballero, Nelson Eduardo Duran
|
Abstract
Disclosed is a method of obtaining an inorganic nanostructured complex (CFI-1), a protein-associated nanostructured complex (MRB-CFI-1) and antitumor use. The main use is in treating urinary bladder cancer, both in animals and humans. The complex has singular antitumor activity, and can potentially be used as a substitute and/or act as an adjuvant for other commercial antineoplastic drugs.
IPC Classes ?
- C01C 1/02 - Preparation or separation of ammonia
- A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00 - Antineoplastic agents
- A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- C01B 25/02 - Preparation of phosphorus
- C01F 5/32 - Preparation of anhydrous magnesium chloride by chlorinating magnesium compounds
- A61K 38/00 - Medicinal preparations containing peptides
- B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- B82Y 40/00 - Manufacture or treatment of nanostructures
|
|
